Ratings Eurofins Scientific SE Deutsche Boerse AG

Equities

ESF

FR0000038259

End-of-day quote Deutsche Boerse AG Other stock markets 23:00:00 04/02/2024 GMT			5-day change	1st Jan Change
53.62 ^EUR	-1.07%		-4.59%	-9.73%

04-29	CAC40: France's rating maintained = non-event	CF
04-29	CAC40: starts the week slightly up, crosses the 8100 mark	CF

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The earnings growth currently anticipated by analysts for the coming years is particularly strong.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

The company is in debt and has limited leeway for investment
With a 2024 P/E ratio at 27.59 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last few months, analysts have been revising downwards their earnings forecast.

Ratings chart - Surperformance

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
EUROFINS SCIENTIFIC SE	-9.73%	11.78B		-
HCA HEALTHCARE, INC.	+13.70%	80.61B		C+
CVS HEALTH CORPORATION	-29.20%	70.18B		B-
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+9.72%	29.08B		C+
LABORATORY CORPORATION OF AMERICA HOLDINGS	-11.43%	16.97B		B
FRESENIUS SE & CO. KGAA	-0.43%	16.96B		A-
QUEST DIAGNOSTICS INCORPORATED	-0.31%	15.26B		A-
FRESENIUS MEDICAL CARE AG	+3.42%	12.41B		A-
PURE HEALTH HOLDING	-30.70%	11.95B	-	-
REDE D'OR SÃO LUIZ S.A.	-6.75%	11.93B		B-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes